Enzymatica AB (XSAT:ENZY) Interest Expense : kr-2.46 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Enzymatica AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Enzymatica AB's interest expense for the three months ended in Mar. 2024 was kr -0.79 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr-2.46 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Enzymatica AB's Operating Income for the three months ended in Mar. 2024 was kr -18.41 Mil. Enzymatica AB's Interest Expense for the three months ended in Mar. 2024 was kr -0.79 Mil. Enzymatica AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enzymatica AB Interest Expense Historical Data

The historical data trend for Enzymatica AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymatica AB Interest Expense Chart

Enzymatica AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.35

-0.80

-0.89

-1.00

-2.09

Enzymatica AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-0.44	-0.57	-0.45	-0.66	-0.79

Enzymatica AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.46 Mil.

Enzymatica AB (XSAT:ENZY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Enzymatica AB's Interest Expense for the three months ended in Mar. 2024 was kr-0.79 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-18.41 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was kr25.32 Mil.

Enzymatica AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Enzymatica AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Enzymatica AB (XSAT:ENZY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Enzymatica AB (XSAT:ENZY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ENZY:Sweden EN9:Germany

Address

Scheelevagen 19, Delta 5, Ideon Science Park, Lund, SWE, SE-223 70

Website

http://www.enzymatica.se

Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.

Enzymatica AB (XSAT:ENZY) Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016